https://scholars.lib.ntu.edu.tw/handle/123456789/551117
標題: | Improving clinical outcomes of chronic hepatitis B virus infection | 作者: | TUNG-HUNG SU JIA-HORNG KAO |
公開日期: | 2015 | 出版社: | Expert reviews Ltd. | 卷: | 9 | 期: | 2 | 起(迄)頁: | 141-154 | 來源出版物: | Expert review of Gastroenterology and Hepatology | 摘要: | Chronic hepatitis B virus (HBV) infection is a global health problem, leading to cirrhosis, hepatocellular carcinoma (HCC) and liver-related deaths. Universal hepatitis B vaccination is the most cost-effective way to eradicate HBV infection with the remarkable reduction of chronic carriage, neonatal fulminant hepatitis and childhood HCC. The introduction of highly effective antiviral agents, including lamivudine, adefovir dipivoxil, entecavir, telbivudine, tenofovir disoproxil fumarate and pegylated interferons further improve short-, medium- and long-term outcomes of chronic HBV infection, such as ALT normalization, HBV DNA suppression, HBeAg seroconversion, HBsAg seroclearance, fibrosis regression, reduction of cirrhosis, HCC, liver-related deaths and the need for liver transplantation. Above all, sustained and profound viral suppression is the key to improve the clinical outcomes of chronic hepatitis B. ? 2015 Informa UK, Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84921361473&doi=10.1586%2f17474124.2015.960398&partnerID=40&md5=b596fffb23668fa86dbdd03590e07a68 https://scholars.lib.ntu.edu.tw/handle/123456789/551117 |
ISSN: | 1747-4124 | DOI: | 10.1586/17474124.2015.960398 | SDG/關鍵字: | adefovir dipivoxil; alanine aminotransferase; besifovir; emtricitabine; entecavir; hepatitis B vaccine; hepatitis B(e) antigen; immunomodulating agent; lamivudine; nucleoside analog; peginterferon alpha2b; telbivudine; tenofovir alafenamide; tenofovir disoproxil; virus DNA; alanine aminotransferase; antivirus agent; hepatitis B(e) antigen; chronic liver failure; death; drug efficacy; hepatitis B; history; human; liver cell carcinoma; liver cirrhosis; liver fibrosis; liver transplantation; outcome assessment; remission; Review; seroconversion; vaccination; blood; disease management; Hepatitis B, Chronic; treatment outcome; Alanine Transaminase; Antiviral Agents; Disease Management; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。